Philippe GORRY : Citation Profile

Are you Philippe GORRY?

Université de Bordeaux

2

H index

1

i10 index

22

Citations

RESEARCH PRODUCTION:

4

Articles

74

Papers

1

Chapters

RESEARCH ACTIVITY:

   12 years (2010 - 2022). See details.
   Cites by year: 1
   Journals where Philippe GORRY has often published
   Relations with other researchers
   Recent citing documents: 2.    Total self citations: 3 (12 %)

MORE DETAILS IN:
ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/pgo436
   Updated: 2023-11-04    RAS profile: 2022-12-01    
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers

Works with:

Piveteau, Alain (2)

Authors registered in RePEc who have co-authored more than one work in the last five years with Philippe GORRY.

Is cited by:

Bornmann, Lutz (3)

Hall, Bronwyn (1)

Harhoff, Dietmar (1)

Hanks, Andrew (1)

Cites to:

Leydesdorff, Loet (2)

Bornmann, Lutz (2)

Morrill, Melinda (1)

Teixeira, Aurora (1)

evans, william (1)

van Dalen, Hendrik (1)

Bokhari, Farasat (1)

Vieira, Pedro (1)

Main data

Where Philippe GORRY has published?

Journals with more than one article published# docs
Scientometrics2
Revue de la Rgulation - Capitalisme, institutions, pouvoirs2

Working Papers Series with more than one paper published# docs
Post-Print / HAL72

Recent works citing Philippe GORRY (2023 and 2022)

YearTitle of citing document
2022Identifying keyword sleeping beauties: A perspective on the knowledge diffusion process. (2022). Zhang, LI ; Huang, Shengzhi ; Lu, Wei ; Bu, YI ; Yang, Jinqing. In: Journal of Informetrics. RePEc:eee:infome:v:16:y:2022:i:1:s1751157721001103.

Full description at Econpapers || Download paper

2022Exploring the “awakening effect” in knowledge diffusion: a case study of publications in the library and information science domain. (2022). Liu, Yijun ; Tang, Xianyi ; Chi, Yuxue. In: Journal of Informetrics. RePEc:eee:infome:v:16:y:2022:i:4:s1751157722000943.

Full description at Econpapers || Download paper

Works by Philippe GORRY:

YearTitleTypeCited
2012Construction politique des marchés et politiques des prix. Le cas de lindustrie pharmaceutique In: Post-Print.
[Citation analysis]		paper0
2011Regulating the drugs market in the EU: the contradiction between safety, innovation and access to care In: Post-Print.
[Citation analysis]		paper0
2011Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS) In: Post-Print.
[Citation analysis]		paper0
2013CH2 Une demande structurée par les prescripteur & CH3 Un système dominé par les firmes multinationales pharmaceutiques In: Post-Print.
[Citation analysis]		paper0
2010The political construction of orphan drugs market: between innovation & access to care In: Post-Print.
[Citation analysis]		paper0
2010Impact of market exclusivity versus IP protection in fostering innovation for rare diseases In: Post-Print.
[Citation analysis]		paper0
2012Schéma régional de lenseignement supérieur, de la recherche & de linnovation In: Post-Print.
[Citation analysis]		paper0
2018Exploring the historical roots of mesenchymal stem cell research using reference publication year spectroscopy In: Post-Print.
[Citation analysis]		paper0
2016Health innovation for rare diseases In: Post-Print.
[Citation analysis]		paper1
2014Building an orphan drug market database to enpower decision making by patient organizations & pharma-biotech companies In: Post-Print.
[Citation analysis]		paper0
2014Les enjeux de la reconnaissance de la radiologie interventionnelle : un travail de recherche interdisciplinaire (sociologie, économie, droit) In: Post-Print.
[Citation analysis]		paper0
2015Construction of mental health categories In: Post-Print.
[Full Text][Citation analysis]		paper1
2015Mapping scientific dynamics in « Regenerative Medicine » research, Tissue Engineering Part A, 21, S1 In: Post-Print.
[Citation analysis]		paper0
2014Institutionnalisation des politiques publiques de santé & diffusion de l’innovation médicale In: Post-Print.
[Citation analysis]		paper0
2014Approche quantitative de la diffusion d’un innovation: exemple de la radiologie interventionnelle In: Post-Print.
[Citation analysis]		paper0
2014Institutionalizarion of public policies & diffusion of innovation: the case of interventional radiology In: Post-Print.
[Citation analysis]		paper0
2014Diagnostic prénatal non invasif sur sang maternel & Propriété Intellectuelle: entre éthique de la santé et efficience du marché In: Post-Print.
[Citation analysis]		paper0
2015Intellectual Property Rights and Traditional Knowledge: to which extend biodiversity is preempted at the global level In: Post-Print.
[Citation analysis]		paper0
2015Charles Dotter & the birth of Interventional Radiology: A sleeping beauty with a restless sleep In: Post-Print.
[Citation analysis]		paper0
2015L’histoire de la radiologie interventionnelle: développement et diffusion d’une innovation médicale In: Post-Print.
[Citation analysis]		paper0
2016Orphan Drug Designations as valuable Intangible assets for IPO Investors in Pharma-Biotech Companies In: Post-Print.
[Citation analysis]		paper0
2015Orphan Drug Designations as Valuable intangible assets for Ipo Investors in Pharma-biotech companies.(2015) In: Post-Print.
[Citation analysis]
This paper has another version. Agregated cites: 0		paper
2018Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies.(2018) In: NBER Chapters.
[Full Text][Citation analysis]
This paper has another version. Agregated cites: 0		chapter
2017Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies..(2017) In: NBER Working Papers.
[Full Text][Citation analysis]
This paper has another version. Agregated cites: 0		paper
2016Serendipity and university technology transfer: a case study. In: Post-Print.
[Citation analysis]		paper0
2016Empirical economic analysis of orphan drug legislation impact on innovation In: Post-Print.
[Citation analysis]		paper0
2016Empirical Economic Analysis of Orphan Drug Legislation Impact on Innovation.(2016) In: Post-Print.
[Citation analysis]
This paper has another version. Agregated cites: 0		paper
2016Pharma Competitive Intelligence using open source data and visualization tool: towards metrics for drug R&D milestones In: Post-Print.
[Citation analysis]		paper0
2016Biodiversity Sustainability of Phytomedicine Research: a 3-dimensions analysis around the North-South divide In: Post-Print.
[Citation analysis]		paper0
2016Empirical Economic Analysis of Orphan Drug Innovation In: Post-Print.
[Citation analysis]		paper0
2017Empirical Economic Analysis of Orphan Drug Innovation.(2017) In: Post-Print.
[Citation analysis]
This paper has another version. Agregated cites: 0		paper
2016Empirical Economic Analysis of Orphan Drug Innovation.(2016) In: Post-Print.
[Citation analysis]
This paper has another version. Agregated cites: 0		paper
2017Orphan Drugs: Why the US legislation approves more than the EU? In: Post-Print.
[Citation analysis]		paper0
2017Social Recognition of a Medical Innovation: the case of Interventional Radiology in Oncology In: Post-Print.
[Citation analysis]		paper0
2017Neologisms and affiliation name: a bibliometric perspective on the institutionalization of interventional radiology In: Post-Print.
[Citation analysis]		paper0
2017Evolution des prescriptions de médicaments orphelins en cancérologie : en France, et à l’échelle d’un établissement hospitalier In: Post-Print.
[Citation analysis]		paper0
2016Evolution des prescriptions de médicaments orphelins en cancérologie: en France et à l’échelle d’un établissement hospitalier.(2016) In: Post-Print.
[Citation analysis]
This paper has another version. Agregated cites: 0		paper
2018Orphan Drug Market Exclusivity Extension versus Patent Monopoly In: Post-Print.
[Citation analysis]		paper0
2018Does Orphan Drug market exclusivity incentive sustains drug development for rare diseases ? In: Post-Print.
[Citation analysis]		paper0
2018Naming institution after neologism as marker of the institutionalization of new discipline In: Post-Print.
[Citation analysis]		paper0
2018Delayed Recognition in Science: Different Causes of Sleeping and Awakening of Discoveries In: Post-Print.
[Citation analysis]		paper0
2014Ultrasons focalisés de haute intensité : analyse des dynamiques d’innovations In: Post-Print.
[Citation analysis]		paper0
2015Medical literature imprinting by pharma ghost writing: a scientometric evaluation In: Post-Print.
[Citation analysis]		paper0
2015Mapping scientific dynamics in « Regenerative Medicine » research In: Post-Print.
[Citation analysis]		paper0
2015Diffusion of Interventional Radiology and Health Technology Assessment: the case of radiofrequency treatment in oncology In: Post-Print.
[Citation analysis]		paper0
2016Towards a Patent landscaping of Regenerative Medicine In: Post-Print.
[Citation analysis]		paper1
2017Angiogenesis inhibitors drug pipeline landscape In: Post-Print.
[Citation analysis]		paper0
2017Orphan Drug legislation: evaluation of the impact of market exclusivity extension In: Post-Print.
[Citation analysis]		paper0
2017Science and Technology Indicators of Microalgae-Based Biofuel Research In: Post-Print.
[Citation analysis]		paper0
2017The Dissemination of the Concept of “Interventional Radiology” in Medical and Scientific Literature In: Post-Print.
[Citation analysis]		paper0
2017The Dissemination of the Concept of “Interventional Radiology” in Medical and Scientific Literature.(2017) In: Post-Print.
[Citation analysis]
This paper has another version. Agregated cites: 0		paper
2018Impact of Health Technology Assessment on Innovation Diffusion: the case of techniques in Interventional Radiology. In: Post-Print.
[Citation analysis]		paper0
2019Market Valuation of FDA Orphan Drug Regulatory Events In: Post-Print.
[Citation analysis]		paper2
2019Global overview of patenting landscape in unmanned aerial vehicles. In: Post-Print.
[Citation analysis]		paper0
2019Drug Safety scientometrics overview highlights public health issues. In: Post-Print.
[Citation analysis]		paper0
2013HTA National Public Policy and Their Socio-Economic Environment: A European Perspective In: Post-Print.
[Citation analysis]		paper0
2019R&D incentives and innovation spillovers: evidence from the European orphan drug regulation. In: Post-Print.
[Citation analysis]		paper0
2013Analyse sectorielle, technologique et économique, du marché des médicaments orphelins. In: Post-Print.
[Citation analysis]		paper0
2013A patent landscaping of medicinal plants extracts In: Post-Print.
[Citation analysis]		paper0
2013The scientific-knowledge based institutionalization of Health Technology Assessment: a bibliometric and network analysis In: Post-Print.
[Citation analysis]		paper0
2016Website: orphandrugseconomics.org In: Post-Print.
[Citation analysis]		paper0
2016Economie de la santé : les médicaments orphelins In: Post-Print.
[Citation analysis]		paper0
2020Pourquoi les prix des traitements contre les maladies rares deviennent fous ? In: Post-Print.
[Citation analysis]		paper0
2019Atelier Accès à linnovation In: Post-Print.
[Citation analysis]		paper0
2015Does scientific knowledge play a role in public policies? A contribution of scientometrics to political science: the case of HTA In: Post-Print.
[Citation analysis]		paper0
2015Naissances de la radiologie interventionnelle. Le rôle de Charles T. Dotter In: Post-Print.
[Citation analysis]		paper0
2020Impact de la législation européenne des médicaments orphelins sur le marché global du médicament In: Post-Print.
[Citation analysis]		paper0
2020Assessment of generic competition for Orphan Drugs marketed in the US (1993-2019) In: Post-Print.
[Citation analysis]		paper0
2020Le statut de médicament orphelin est un signal positif pour les investisseurs lors de lintroduction en bourse des sociétés de biotechnologie In: Post-Print.
[Citation analysis]		paper0
2020Médicaments orphelins et maladies rares sur Twitter In: Post-Print.
[Citation analysis]		paper0
2021Beyond health security dependencies. Rethinking public health and industrial policies construction In: Post-Print.
[Citation analysis]		paper0
2022Drug shortages, APIs supply & Pharma Global Value Chain In: Post-Print.
[Citation analysis]		paper0
2013Health Technology Assessment Agencies and their economic environment: a European perspective. In: Post-Print.
[Citation analysis]		paper0
2014The EUs Government of Pharmaceuticals: Incompleteness Embraced In: Post-Print.
[Citation analysis]		paper0
2017Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies. NBER working paper n° w24021. In: Working Papers.
[Citation analysis]		paper0
2015La construction des catégories diagnostiques de maladie mentale In: Revue de la Régulation - Capitalisme, institutions, pouvoirs.
[Full Text][Citation analysis]		article0
2021Sécurité sanitaire sous dépendance. Une construction politique à repenser In: Revue de la Régulation - Capitalisme, institutions, pouvoirs.
[Full Text][Citation analysis]		article0
2016“Sleeping beauty” and her restless sleep: Charles Dotter and the birth of interventional radiology In: Scientometrics.
[Full Text][Citation analysis]		article10
2018Delayed recognition of Judah Folkman’s hypothesis on tumor angiogenesis: when a Prince awakens a Sleeping Beauty by self-citation In: Scientometrics.
[Full Text][Citation analysis]		article7

CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated November, 3 2023. Contact: CitEc Team